Literature DB >> 6505969

Biologic considerations and operative strategy in papillary thyroid carcinoma: arguments against the routine performance of total thyroidectomy.

K H Cohn, M Bäckdahl, G Forsslund, G Auer, A Zetterberg, G Lundell, P O Granberg, T Löwhagen, J S Willems, B Cady.   

Abstract

Reasons cited for the routine performance of total thyroidectomy in patients with papillary thyroid carcinoma include: fear of multicentric neoplastic foci causing local recurrence and death; risk of anaplastic transformation of unresected multifocal microscopic carcinoma; toxicity of high-dose radioactive iodine to ablate normal thyroid remnants; and lack of reliable criteria for grading malignancy and identifying patients at high risk. However, autopsy studies have detected microscopic foci of papillary thyroid cancer as incidental findings in up to 24% of patients dead of other diseases. The prevalence of anaplastic transformation of papillary thyroid carcinoma as determined from reports in the literature is less than 1%. A retrospective investigation of 90 patients with papillary thyroid carcinoma derived from the Swedish National Cancer Registry showed no complications from radioiodine ablation of postoperative thyroid remnants in 45 patients. Retrospective analysis of the DNA content of tumors at the time of the initial operation showed a significant difference between a group of 10 patients who died of recurrent and metastatic papillary thyroid carcinoma and a group of 16 patients alive at least 10 years after operation despite distant metastases or recurrent cancer in the thyroid bed and/or cervical lymph nodes. The risk of permanent hypoparathyroidism is higher in patients after total thyroidectomy without apparent improvement in survival rates when compared with less extensive resections. Therefore it is proposed that the criteria for total thyroidectomy in patients with papillary thyroid carcinoma be limited to: tumors that clinically involve both lobes of the thyroid gland, extracapsular spread of cancer requiring enbloc resection, and reoperations where scarring prevents accurate delineation of the extent of the tumor. By differentiating patients at high risk for death from papillary thyroid carcinoma from patients at low risk, the measurement of DNA content may decrease the need for routine total thyroidectomy.

Entities:  

Mesh:

Year:  1984        PMID: 6505969

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  10 in total

1.  Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.

Authors:  K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

2.  The Need for Completion Thyroidectomy in Cases of Differentiated Thyroid Cancer.

Authors:  Bayram Veyseller; Alper Yenigun; Fadlullah Aksoy; Aysenur Meric; Orhan Ozturan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-02-17

3.  Papillary thyroid microcarcinoma: incidence and prognostic factors.

Authors:  Sophie Jacquot-Laperrière; Andrei P Timoshenko; Jean-Marc Dumollard; Michel Peoc'h; Bruno Estour; Christian Martin; Jean-Michel Prades
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-04-13       Impact factor: 2.503

4.  Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study.

Authors:  Gordana Horvatić Herceg; Davorin Herceg; Marko Kralik; Zdenka Bence-Zigman; Hrvojka Tomić-Brzac; Ana Kulić
Journal:  Wien Klin Wochenschr       Date:  2006-10       Impact factor: 1.704

5.  [Radicality principles in operations on malignant thyroid tumors].

Authors:  R A Wahl; P E Goretzki; K Joseph; H D Röher
Journal:  Langenbecks Arch Chir       Date:  1985

6.  Multivariate analysis of risk factors influencing survival in 110 ethnic Chinese with papillary thyroid cancer.

Authors:  T G Lorentz; P W Lau; C Y Lo; W L Law; K Y Wan; I J Lauder
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

7.  DNA cytophotometry in malignant thyroid tumors--use of different evaluation schemes for prognostic statements.

Authors:  H Arps; B Sablotny; M Dietel; A Niendorf; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

8.  Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases.

Authors:  Kenichi Matsuzu; Kiminori Sugino; Katsuhiko Masudo; Mitsuji Nagahama; Wataru Kitagawa; Hiroshi Shibuya; Keiko Ohkuwa; Takashi Uruno; Akifumi Suzuki; Syunsuke Magoshi; Junko Akaishi; Chie Masaki; Michikazu Kawano; Nobuyasu Suganuma; Yasushi Rino; Munetaka Masuda; Kaori Kameyama; Hiroshi Takami; Koichi Ito
Journal:  World J Surg       Date:  2014-01       Impact factor: 3.352

Review 9.  Current Advances in Thyroid Cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?

Authors:  Dagmara Rusinek; Ewa Chmielik; Jolanta Krajewska; Michal Jarzab; Malgorzata Oczko-Wojciechowska; Agnieszka Czarniecka; Barbara Jarzab
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

10.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.